10/05/2007
Opexa Therapeutics to Present at the BIO Investor Forum 200

THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, today announced that David McWilliams, Chief Executive Officer, will present at the BIO Investor Forum 2007 on Thursday, October 11, 2007 at 1:00 p.m. (4:00 p.m. ET) at the Palace Hotel in San Francisco, CA. Mr. McWilliams will provide an overview of the Company and an update on its clinical development programs.

Interested parties can access a live audio webcast and slide presentation by visiting the Investor Relations section of the Company’s website www.opexatherapeutics.com. An archived version of the webcast will be available on the website for 30 days following the presentation.

About Opexa Therapeutics
Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin®, a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for diabetes mellitus. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Permalink: http://www.businesswire.com/news/opexa/20071005005478/en

- - - -